Baker Bros. Advisors LP Ascendis Pharma A/S Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $10.2 Million - $13.5 Million	102,200 Added 2.11%	4,954,855 $605 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $24.3 Million - $36.6 Million	311,051 Added 6.85%	4,852,655 $451 Million
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $113 Million - $177 Million	1,001,334 Added 28.28%	4,541,604 $724 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $20.1 Million - $23.1 Million	150,000 Added 4.42%	3,540,270 $546 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $34.4 Million - $71.9 Million	552,918 Added 19.49%	3,390,270 $399 Million
Q1 2018 May 15, 2018	BUY	$38.98 - $68.04 $8.52 Million - $14.9 Million	218,534 Added 8.34%	2,837,352 $186 Million
Q4 2017 Feb 14, 2018	BUY	$31.98 - $40.38 $8.63 Million - $10.9 Million	269,978 Added 11.49%	2,618,818 $105 Million
Q3 2017 Nov 14, 2017	BUY	$26.89 - $37.1 $63.2 Million - $87.1 Million	2,348,840	2,348,840 $85.1 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.